TY - JOUR
T1 - Prevalence of Ototoxicity Following Hematopoietic Stem Cell Transplantation in Pediatric Patients
AU - Gertson, Kristen
AU - Hayashi, Susan S.
AU - Trinkaus, Kathryn
AU - Wan, Fei
AU - Hayashi, Robert J.
N1 - Funding Information:
Financial disclosure: Data analysis was provided by the Biostatistics Shared Resource of The Siteman Cancer Center, supported in part by National Cancer Institute Cancer Center Support Grant P30 CA091842. Conflict of interest statement: There are no conflicts of interest to disclose.
Funding Information:
Financial disclosure: Data analysis was provided by the Biostatistics Shared Resource of The Siteman Cancer Center, supported in part by National Cancer Institute Cancer Center Support Grant P30 CA091842. Conflict of interest statement: There are no conflicts of interest to disclose. Financial disclosure: See Acknowledgments on page 113.
Publisher Copyright:
© 2019 American Society for Transplantation and Cellular Therapy
PY - 2020/1
Y1 - 2020/1
N2 - The use of hematopoietic stem cell transplantation (HSCT) is increasing for a variety of diseases. Ototoxicity from this procedure has not been extensively studied. A retrospective chart review examined 275 patients from this institution who underwent HSCT between January 1, 2007, and April 30, 2017. Data extracted included therapy before HSCT and the subsequent course of transplantation. Evaluable patients had complete medical records and interpretable audiograms available. Ototoxicity constituted significant threshold changes from baseline or changes in International Society of Pediatric Oncology/Boston Ototoxicity Grading Scale (SIOP) grade comparing audiogram results just before HSCT with those following the transplantation procedure. A total of 147 patients were evaluable. Ototoxicity was observed in 10.2% of the patients. Higher SIOP grade before HSCT was significantly associated with a higher risk of post-transplantation ototoxicity (P <. 01). Previous cisplatin treatment (P <. 0001), but not carboplatin or radiation treatment, was also associated with ototoxicity. Patients with a solid tumor or brain tumor (P <. 0001) and those who received an autologous transplant (P = .0002) were also at increased risk. No post-transplantation event was significantly associated with ototoxicity. Ototoxicity affects a significant percentage of patients undergoing HSCT, and careful monitoring is needed to identify patients impacted by this procedure.
AB - The use of hematopoietic stem cell transplantation (HSCT) is increasing for a variety of diseases. Ototoxicity from this procedure has not been extensively studied. A retrospective chart review examined 275 patients from this institution who underwent HSCT between January 1, 2007, and April 30, 2017. Data extracted included therapy before HSCT and the subsequent course of transplantation. Evaluable patients had complete medical records and interpretable audiograms available. Ototoxicity constituted significant threshold changes from baseline or changes in International Society of Pediatric Oncology/Boston Ototoxicity Grading Scale (SIOP) grade comparing audiogram results just before HSCT with those following the transplantation procedure. A total of 147 patients were evaluable. Ototoxicity was observed in 10.2% of the patients. Higher SIOP grade before HSCT was significantly associated with a higher risk of post-transplantation ototoxicity (P <. 01). Previous cisplatin treatment (P <. 0001), but not carboplatin or radiation treatment, was also associated with ototoxicity. Patients with a solid tumor or brain tumor (P <. 0001) and those who received an autologous transplant (P = .0002) were also at increased risk. No post-transplantation event was significantly associated with ototoxicity. Ototoxicity affects a significant percentage of patients undergoing HSCT, and careful monitoring is needed to identify patients impacted by this procedure.
KW - Ototoxicity
KW - Pediatric
KW - Stem cell transplantation
UR - http://www.scopus.com/inward/record.url?scp=85074508522&partnerID=8YFLogxK
U2 - 10.1016/j.bbmt.2019.08.028
DO - 10.1016/j.bbmt.2019.08.028
M3 - Article
C2 - 31494228
AN - SCOPUS:85074508522
SN - 1083-8791
VL - 26
SP - 107
EP - 113
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
IS - 1
ER -